FinancialContent is the trusted provider of stock market information to the media industry.
June 15, 2009 at 09:59 AM EDT
Amneal Expands Generic Portfolio with Launch of Alprazolam ER and Benazepril HCI Tablets

Amneal Pharmaceuticals is pleased to announce the availability of its Alprazolam Extended Release Tablets in strengths of 0.5 mg, 1 mg, 2 mg and 3 mg. The company also announces the availability of its Benazepril HCI Tablets in strengths of 5 mg, 10 mg, 20 mg and 40 mg.

Alprazolam ER is an anti-anxiety Schedule-IV controlled substance indicated for the treatment of panic disorder with or without agoraphobia. It is an AB-rated, therapeutically equivalent alternative to the brand, Xanax® XR (a trademark of The Upjohn Company). Amneal received U.S. FDA approval to manufacture Alprazolam ER as a result of acquiring Interpharm’s strong product line last year. The Amneal generic is available in a 60-count size for all strengths, which will begin shipping on June 15, 2009.

Amneal has also been granted FDA approval to manufacture Benazepril HCI. Benazepril HCI is an AB-rated, bioequivalent alternative to the brand, Lotensin® (a trademark of Ciba-Geigy), and is indicated for the treatment of hypertension. All four strengths of the generic are available in 100- and 500-count sizes, which began shipping on June 1, 2009.

“The introduction of Alprazolam ER and Benazepril HCI supports Amneal’s growth strategy of adding diverse, more sophisticated lines such as modified release medications, controlled substances and hormonal products,” said Jim Luce, Amneal Executive Vice President, Sales & Marketing. He continued, “Amneal’s rapidly expanding portfolio of high quality products and dedication to customer service are enabling us to develop a significant presence in the generic prescription marketplace.”

Amneal Pharmaceuticals LLC, headquartered in Paterson, NJ, is a U.S.-based firm that develops, manufactures and distributes generic pharmaceuticals regulated and approved by the U.S. FDA. Known as “Generic’s New Generation”, the company utilizes its newly expanded R&D and manufacturing capabilities to conceive breakthrough developments with lasting impact for a robust product pipeline. Rapid ANDA approvals and diverse product acquisitions are key to Amneal’s aggressive growth strategy, as is the company’s strong commitment to deep customer relationships and maximum value creation. Amneal delivers high quality products, superior service levels and dynamic value throughout the pharmaceutical industry. For more information, visit www.amneal.com.

Contacts:

Amneal Pharmaceuticals, LLC
Jim Luce
Executive Vice President, Sales & Marketing
Direct: 949-610-8018
Fax: 949-610-8218
jim@amneal.com
www.amneal.com
620 Newport Center Drive, 14th Floor
Newport Beach, California 92660
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here
   
Financial Widgets

Display market data, financial news or stock quotes - Learn More

Advertising Network

Advertise on FinancialContent's huge network - Learn More

Web Services

Power your internet and wireless applications - Learn More